Literature DB >> 8742486

GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.

J Opacka-Juffry1, S Ashworth, S P Hume, D Martin, D J Brooks, S B Blunt.   

Abstract

We have investigated whether glial cell line-derived neurotrophic factor (GDNF) protects against a complete unilateral 6-hydroxydopamine (6-OHDA) nigrostriatal lesion, a robust rat model of Parkinson's disease. GDNF or vehicle were administered above the rat substantia nigra and into the lateral ventricle immediately before an ipsilateral 6-OHDA injection into the medial forebrain bundle. In vivo tests were employed to assess the effects of the treatment: microdialysis to measure striatal dopamine release, amphetamine challenge to estimate turning behaviour, and positron emission tomography (PET) to image dopamine reuptake sites. The present results show that GDNF can protect dopaminergic neurones against an acute and irreversible 6-OHDA lesion. They are encouraging for potential use of GDNF in Parkinson's disease.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8742486

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  10 in total

1.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

2.  Lack of permanent nigrostriatal dopamine deficit following 6-hydroxydopamine injection into the rat striatum. Short communication.

Authors:  J Opacka-Juffry; S Ashworth; A M Sullivan; R B Banati; S B Blunt
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Neuroprotective effect of fasudil on inflammation through PI3K/Akt and Wnt/β-catenin dependent pathways in a mice model of Parkinson's disease.

Authors:  Yongfei Zhao; Qiong Zhang; Jianying Xi; Baoguo Xiao; Yanhua Li; Cungen Ma
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

4.  GDNF selectively protects dopamine neurons over serotonin neurons against the neurotoxic effects of methamphetamine.

Authors:  W A Cass
Journal:  J Neurosci       Date:  1996-12-15       Impact factor: 6.167

5.  Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

Authors:  R J Mandel; S K Spratt; R O Snyder; S E Leff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

6.  GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.

Authors:  W A Cass; M W Manning
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

Review 7.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

8.  Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra.

Authors:  J Andrés Abin-Carriquiry; Ronald McGregor-Armas; Gustavo Costa; Jessika Urbanavicius; Federico Dajas
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

Review 9.  Animal models of neurodegenerative disease: insights from in vivo imaging studies.

Authors:  Elissa M Strome; Doris J Doudet
Journal:  Mol Imaging Biol       Date:  2007 Jul-Aug       Impact factor: 3.484

Review 10.  Neuroprotective Surgical Strategies in Parkinson's Disease: Role of Preclinical Data.

Authors:  Napoleon Torres; Jenny Molet; Cecile Moro; John Mitrofanis; Alim Louis Benabid
Journal:  Int J Mol Sci       Date:  2017-10-20       Impact factor: 5.923
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.